This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Kisolite Corp.

Profile

Kisolite Corp is a privately held Canadian biotechnology business to business R&D company. The company aims to commercialize a natural, novel bioactive mineral clay as an active ingredient for the pharmaceutical dermatology market and the consumer health skin-health market. The active ingredient is exclusively sourced by the company from a sustainably harvested inventory of raw material located at the Central West Coast of British Columbia, Canada and produced with proprietary technology at the Company’s modern GMP compliant production facility in Squamish, British Columbia, Canada. The processed mineral clay is marketed under the name “Kisolite”. With exclusive global rights to the raw mineral clay material and proprietary rights to processed “Kisolite”, the Company is highly invested in research and development to expand and support the field of use opportunities for Kisolite. The Company is seeking interested partners in the pharmaceutical and consumer health skin health markets to support further development and commercialization for Kisolite. Pre-clinical datasets will be made available to pre-qualified parties interested in licensing and joint development opportunities based on dermatology sub-markets acne, psoriasis, atopic dermatitis and general skin health. The results of pre-clinical data show that Kisolite demonstrates strong efficacy in treating these disorders, which offer numerous opportunities for pharmaceutical product development in this health sector.